Thus, we explored the possible associations between cerebrospinal fluid (CSF), NFL/BDNF levels, and clinical features of MS to assess the potential biomarker value of these molecules in predicting and monitoring AMS development. The gene discussed is NEFL; the disease is ablepharon macrostomia syndrome.